Lympho-myeloid chimerism achieved by spleen graft of green fluorescent protein transgenic rat in a combined pancreas transplantation model (TI03-029)

2004 ◽  
Vol 12 (2) ◽  
pp. 115-122 ◽  
Author(s):  
Y Sakuma
2001 ◽  
Vol 286 (4) ◽  
pp. 779-785 ◽  
Author(s):  
Yoji Hakamata ◽  
Kazunori Tahara ◽  
Hiroo Uchida ◽  
Yasunaru Sakuma ◽  
Masahiko Nakamura ◽  
...  

2010 ◽  
Vol 24 (7) ◽  
pp. 645-656 ◽  
Author(s):  
Teresa C. Moloney ◽  
Peter Dockery ◽  
Anthony J. Windebank ◽  
Frank P. Barry ◽  
Linda Howard ◽  
...  

Background. A major technical limitation in preclinical cell replacement research is the ability to discriminate between donor and host tissue after transplantation. This problem has been lessened by the availability of transgenic animals that express “reporter” genes, such as green fluorescent protein (GFP). Objective. We determined the usefulness of one such transgenic reporter rat to assess the survival of bone marrow—derived rat mesenchymal stem cells (MSCs) following direct transplantation into the intact adult brain. We also sought to determine if the expression of GFP in the brain affected the survival of the MSCs or the host’s neuroimmune response to the cells. Methods. Rats received intrastriatal injections of sterile transplantation medium, 100 000 normal MSCs, or 100 000 GFP-MSCs and were killed humanely 1, 4, 7, 28, and 42 days posttransplantation for astrocyte and microglial immunohistochemical staining. Results. GFP-MSCs were evident at each examination, although their survival declined over time. Graft volume estimates comparing normal and GFP-MSCs revealed that GFP expression did not adversely affect the survival of the stem cells in the brain. Furthermore, immunostaining for astrocytes and microglia revealed that expression of the reporter protein did not affect the immunogenicity of the stem cells. Conclusions. These data indicate the usefulness of GFP for investigating the survival of MSCs following transplantation to the brain. However, the mechanisms responsible for the poor survival of the stem cells must be elucidated if these cells are to serve cell-based therapies for neurodegenerative disorders.


Sign in / Sign up

Export Citation Format

Share Document